Adial Pharmaceuticals Inc (ADIL)
NASDAQ:ADIL
ADIL Stock Chart & Stats
$0.22
-$0.03(-2.80%)
At close: 4:00 PM EST
$0.22
-$0.03(-2.80%)
Day’s Range― - ―
52-Week Range$1.54 - $30.25
Previous CloseN/A
Volume36.45K
Average Volume (3M)746.19K
Market Cap
$2.24M
Enterprise Value-$4.37M
Total Cash (Recent Filing)$5.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 20, 2026EPS Estimate
-2.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding1,427,970
10 Day Avg. Volume779,793
30 Day Avg. Volume746,186
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap-1.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.46K
Enterprise Value/Ebitda0.56
Forecast
1Y Price Target
$8.00Price Target Upside3536.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-6.73
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial CollaborationA collaboration with Molteni supplies European regulatory, manufacturing, and commercial infrastructure plus structured royalties and milestones tied to late-stage success, which could accelerate European market entry.
Genomic DiagnosticA validated cheek-swab genomic test identifies the AG+ patient subgroup for targeted recruitment and potential labeling of a responsive population, improving trial efficiency and commercial targeting.
Regulatory PathwayRegulatory guidance that may permit approval based on a single well-controlled pivotal study plus confirmatory evidence could shorten development timelines and lower late-stage program costs.
Bears Say
Equity DilutionExpected shareholder dilution from ongoing capital raises to fund the late-stage program could reduce existing holders' value and pressure the stock.
Liquidity RiskReported net loss and a modest cash position point to near-term financing needs to support the planned late-stage study, creating risk if new funding is not secured.
Adial Pharmaceuticals News
ADIL FAQ
What was Adial Pharmaceuticals Inc’s price range in the past 12 months?
Adial Pharmaceuticals Inc lowest stock price was $1.54 and its highest was $30.25 in the past 12 months.
What is Adial Pharmaceuticals Inc’s market cap?
Adial Pharmaceuticals Inc’s market cap is $2.24M.
When is Adial Pharmaceuticals Inc’s upcoming earnings report date?
Adial Pharmaceuticals Inc’s upcoming earnings report date is May 20, 2026 which is in 36 days.
How were Adial Pharmaceuticals Inc’s earnings last quarter?
Adial Pharmaceuticals Inc released its earnings results on Mar 06, 2026. The company reported -$1.81 earnings per share for the quarter, beating the consensus estimate of -$2.13 by $0.32.
Is Adial Pharmaceuticals Inc overvalued?
According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Undervalued.
Does Adial Pharmaceuticals Inc pay dividends?
Adial Pharmaceuticals Inc does not currently pay dividends.
What is Adial Pharmaceuticals Inc’s EPS estimate?
Adial Pharmaceuticals Inc’s EPS estimate is -2.25.
How many shares outstanding does Adial Pharmaceuticals Inc have?
Adial Pharmaceuticals Inc has 1,427,970 shares outstanding.
What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?
Adial Pharmaceuticals Inc reported an EPS of -$1.81 in its last earnings report, beating expectations of -$2.13. Following the earnings report the stock price went down -7.107%.
Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ADIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
ADIL Stock 12 Month Forecast
Average Price Target
$8.00
▲(3536.36% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Alzamend Neuro
―
Calidi Biotherapeutics
―